DBV Technologies: Before it was cool

News published on July Tuesday 11, 2017
Share on

DBV Technologies is at an inflection point with the readout of the phase III trial for its lead product, Viaskin Peanut, in the upcoming months. We believe this late-stage trial has been significantly de-risked and we expect positive results to trigger a significant re-rating of the stock, primarily stemming from: 1/ the company’s business model to transition from a biotech into an integrated biopharma within the next 18 months and 2/ more emphasis to be put on the application of the EPIT platform beyond peanuts and even beyond food allergies. Our new Fair Value is EUR105, implying over 60% upside to the current share price.

Click here to download our latest findings >>

For more information, please contact marketing@bryangarnier.com

The Essentials

Everything you need to know about investment banking dedicated to growth
Stay Informed
Get our news
Join our Team
Bryan, Garnier & Co is always looking for talent in all our divisions, at all levels
Explore our opportunities